Literature DB >> 26933087

Identification of RNA-Binding Protein LARP4B as a Tumor Suppressor in Glioma.

Hideto Koso1, Hungtsung Yi1, Paul Sheridan2, Satoru Miyano2, Yasushi Ino3, Tomoki Todo3, Sumiko Watanabe4.   

Abstract

Transposon-based insertional mutagenesis is a valuable method for conducting unbiased forward genetic screens to identify cancer genes in mice. We used this system to elucidate factors involved in the malignant transformation of neural stem cells into glioma-initiating cells. We identified an RNA-binding protein, La-related protein 4b (LARP4B), as a candidate tumor-suppressor gene in glioma. LARP4B expression was consistently decreased in human glioma stem cells and cell lines compared with normal neural stem cells. Moreover, heterozygous deletion of LARP4B was detected in nearly 80% of glioblastomas in The Cancer Genome Atlas database. LARP4B loss was also associated with low expression and poor patient survival. Overexpression of LARP4B in glioma cell lines strongly inhibited proliferation by inducing mitotic arrest and apoptosis in four of six lines as well as in two patient-derived glioma stem cell populations. The expression levels of CDKN1A and BAX were also upregulated upon LARP4B overexpression, and the growth-inhibitory effects were partially dependent on p53 (TP53) activity in cells expressing wild-type, but not mutant, p53. We further found that the La module, which is responsible for the RNA chaperone activity of LARP4B, was important for the growth-suppressive effect and was associated with BAX mRNA. Finally, LARP4B depletion in p53 and Nf1-deficient mouse primary astrocytes promoted cell proliferation and led to increased tumor size and invasiveness in xenograft and orthotopic models. These data provide strong evidence that LARP4B serves as a tumor-suppressor gene in glioma, encouraging further exploration of the RNA targets potentially involved in LARP4B-mediatd growth inhibition. Cancer Res; 76(8); 2254-64. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26933087     DOI: 10.1158/0008-5472.CAN-15-2308

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Role of the RNA-binding protein La in cancer pathobiology.

Authors:  Gunhild Sommer; Tilman Heise
Journal:  RNA Biol       Date:  2020-07-20       Impact factor: 4.652

2.  DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.

Authors:  Christine Aaserød Pedersen; Maria Dung Cao; Thomas Fleischer; Morten B Rye; Stian Knappskog; Hans Petter Eikesdal; Per Eystein Lønning; Jörg Tost; Vessela N Kristensen; May-Britt Tessem; Guro F Giskeødegård; Tone F Bathen
Journal:  Breast Cancer Res       Date:  2022-06-24       Impact factor: 8.408

Review 3.  Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

Authors:  Shakur Mohibi; Xinbin Chen; Jin Zhang
Journal:  Pharmacol Ther       Date:  2019-07-11       Impact factor: 12.310

Review 4.  The La and related RNA-binding proteins (LARPs): structures, functions, and evolving perspectives.

Authors:  Richard J Maraia; Sandy Mattijssen; Isabel Cruz-Gallardo; Maria R Conte
Journal:  Wiley Interdiscip Rev RNA       Date:  2017-08-07       Impact factor: 9.957

5.  Development and Validation of a RNA Binding Protein-Associated Prognostic Model for Hepatocellular Carcinoma.

Authors:  Ming Wang; Feng Jiang; Ke Wei; Jimei Wang; Guoping Zhou; Chuyan Wu; Guoyong Yin
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

Review 6.  RNA Binding Protein as an Emerging Therapeutic Target for Cancer Prevention and Treatment.

Authors:  Suntaek Hong
Journal:  J Cancer Prev       Date:  2017-12-30

7.  A pan-cancer genome-wide analysis reveals tumour dependencies by induction of nonsense-mediated decay.

Authors:  Zhiyuan Hu; Christopher Yau; Ahmed Ashour Ahmed
Journal:  Nat Commun       Date:  2017-06-26       Impact factor: 14.919

8.  Spontaneous development of intratumoral heterogeneity in a transposon-induced mouse model of glioma.

Authors:  Keisuke Sumiyoshi; Hideto Koso; Sumiko Watanabe
Journal:  Cancer Sci       Date:  2018-04-15       Impact factor: 6.716

9.  Cancer astrocytes have a more conserved molecular status in long recurrence free survival (RFS) IDH1 wild-type glioblastoma patients: new emerging cancer players.

Authors:  Sara Franceschi; Francesca Lessi; Paolo Aretini; Valerio Ortenzi; Cristian Scatena; Michele Menicagli; Marco La Ferla; Prospero Civita; Katia Zavaglia; Claudia Scopelliti; Alessandro Apollo; Francesco Giovanni Carbone; Riccardo Vannozzi; Generoso Bevilacqua; Francesco Pasqualetti; Antonio Giuseppe Naccarato; Chiara Maria Mazzanti
Journal:  Oncotarget       Date:  2018-05-08

10.  RNA helicase DHX15 acts as a tumour suppressor in glioma.

Authors:  Shingo Ito; Hideto Koso; Kazuhiro Sakamoto; Sumiko Watanabe
Journal:  Br J Cancer       Date:  2017-08-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.